Finnish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Keto-diet for Intubated Critical Care COVID-19

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
Linkki tallennetaan leikepöydälle
TilaEi vielä rekrytoinnissa
Sponsorit
Johns Hopkins University

Avainsanat

Abstrakti

Coronavirus disease (COVID-2019) is a devastating viral illness that originated in Wuhan China in late 2019 and there are nearly 2 million confirmed cases. The mortality rate is approximately 5% of reported cases and over half of patients that require mechanical ventilation for respiratory failure. As the disease continues to spread, strategies for reducing duration of ventilator support in patients with COVID-19 could significantly reduce morbidity and mortality of these individuals and future patients requiring this severely limited life-saving resource. Methods to improve gas exchange and to reduce the inflammatory response in COVID-19 are desperately needed to save lives.
The ketogenic diet is a high fat, low carbohydrate, adequate-protein diet that promotes metabolic ketosis (ketone body production) through hepatic metabolism of fatty acids. High fat, low carbohydrate diets have been shown to reduce duration of ventilator support and partial pressure carbon dioxide in patients with acute respiratory failure. In addition, metabolic ketosis reduces systemic inflammation. This mechanism could be leveraged to halt the cytokine storm characteristic of COVID-19 infection.
The hypothesis of this study is that the administration of a ketogenic diet will improve gas exchange, reduce inflammation, and duration of mechanical ventilation. The plan is to enroll 15 intubated patients with COVID 19 infection and administer a 4:1 ketogenic formula during their intubation.

Kuvaus

Coronavirus disease (COVID-2019) is a devastating viral illness that originated in Wuhan China in late 2019. The number of confirmed cases worldwide has nearly reached 2 million and more than 125,000 people have died. Early studies from Wuhan reported a mortality rate of 2-3% with lower rates in surrounding provinces as the disease spread (closer to 0.7% of confirmed cases). One hypothesized cause for the higher mortality rate in Wuhan compared to surrounding regions was the rapid "surge" of COVID-19 infections before the disease was identified and social distancing implemented. Critically ill patients developed acute respiratory distress syndrome with inflammatory pulmonary edema and life-threatening hypoxemia requiring mechanical ventilation. This resulted in a significant strain on health-care resources such as availability of mechanical ventilators to treat patients with acute respiratory failure. As the disease spreads worldwide, strategies for reducing duration of ventilator support in patients with COVID-19 could significantly reduce morbidity and mortality of these individuals and future patients requiring this severely limited life-saving resource.

Alterations in macronutrient composition may be leveraged to improve ventilation and inflammation in COVID-19 patients. The ketogenic diet is a high fat, low carbohydrate, adequate protein diet that promotes ketone body production through hepatic metabolism of fatty acids. High fat, low carbohydrate diets have been shown to reduce duration of ventilator support and partial pressure carbon dioxide in patients with acute respiratory failure. Switching from glucose to fat oxidation lowers the respiratory quotient, thereby reducing the amount of carbon dioxide produced. This reduces ventilator demands and may improve oxygenation by lowering alveolar carbon dioxide levels, ultimately reducing time on mechanical ventilation. A study published in 1989 compared 10 participants intubated for acute respiratory failure and randomized to a high-fat, low carbohydrate diet and 10 participants receiving a standard isocaloric, isonitrogenous diet and showed a decrease in the partial pressure of carbon dioxide of 16% in the ketogenic diet group compared to a 4% increase in the standard diet group (p=0.003). The patients in the high-fat diet group had a mean of 62 fewer hours on a ventilator (p = 0.006) compared to the control group.

The high-fat diet used in the study had a ratio of 1.2:1 fat to protein and carbohydrate combined in grams. The ketogenic diet, which has been used safely and effectively in patients with chronic epilepsy for nearly one century and more recently in critically ill, intubated patients for the management of refractory and super-refractory status epilepticus has a 4:1 ratio (90% fat kilocalories). While a 1:1 ratio diet can produce a state of mild metabolic ketosis (typically ~ 1 mmol/L of the ketone body betahydroxybutyrate, measured in serum), a higher 4:1 ratio ketogenic diet can produce higher ketone body betahydroxybutyrate levels and more rapidly (up to 2 mmol/L within 24 hours of initiation). One study of obese patients treated with ketogenic diet reported that increases in ketone body production correlated with a lower partial pressure of carbon dioxide levels. A more recent study showed that patients with refractory epilepsy had a reduction in the respiratory quotient and increased fatty acid oxidation without a change in the respiratory energy expenditure with chronic use of the ketogenic diet. These findings were replicated in healthy subjects on ketogenic diet compared to a control group and patients on a ketogenic diet also had a significant reduction in carbon dioxide output and partial pressure of carbon dioxide. The authors concluded that a ketogenic diet may decrease carbon dioxide body stores and that use of a ketogenic diet may be beneficial for patients with respiratory failure. Even in patients without hypercapnia (primarily hypoxic respiratory failure), lowering carbon dioxide production permits lowering tidal volumes - a cornerstone of acute respiratory distress syndrome management.

In addition to reducing the partial pressure of carbon dioxide, metabolic ketosis reduces systemic inflammation. This mechanism could be leveraged to halt the cytokine storm characteristic of COVID-19 infection. Several studies provide evidence that pro-inflammatory cytokine production is significantly reduced in animals fed a ketogenic diet in a variety of disease models. In a rodent model of Parkinson's disease, mice were found to have significantly decreased levels of pro-inflammatory, macrophage secreted cytokines interleukin-1β, interleukin-6, and Tumor necrosis factor-alpha after 1 week of treatment with a ketogenic diet. Likewise, rats pretreated with a ketogenic diet prior to injection with lipopolysaccharide to induce fever did not experience an increase in body temperature or interleukin-1β, while significant increases were seen in control animals not pretreated with a ketogenic diet. In a mouse model of NLRP3-mediated diseases as well as human monocytes, the ketone body beta-hydroxybutyrate inhibited the NLRP3 inflammasome-mediated production of interleukin-1β and interleukin-18. These findings have been replicated in several recent animal studies and preliminary studies in humans. The hypothesis of this study is that through induction of metabolic ketosis combined with carbohydrate restriction, a ketogenic diet is protective against the cytokine storm in COVID-19. With its carbon dioxide-lowering and anti-inflammatory properties, a ketogenic diet may become an important component of the acute respiratory distress syndrome arsenal with immediate relevance to the current COVID-19 pandemic.

Päivämäärät

Viimeksi vahvistettu: 05/31/2020
Ensimmäinen lähetys: 04/15/2020
Arvioitu ilmoittautuminen lähetetty: 04/19/2020
Ensimmäinen lähetetty: 04/23/2020
Viimeisin päivitys lähetetty: 06/14/2020
Viimeisin päivitys lähetetty: 06/16/2020
Todellinen opintojen alkamispäivä: 08/31/2020
Arvioitu ensisijainen valmistumispäivä: 08/31/2021
Arvioitu tutkimuksen valmistumispäivä: 12/30/2021

Ehto tai tauti

COVID-19

Interventio / hoito

Dietary Supplement: Intubated patients with COVID-19 on a ketogenic diet only

Other: Intubated patients with COVID-19 on a ketogenic diet only

Vaihe

-

Varren ryhmät

VarsiInterventio / hoito
Experimental: Intubated patients with COVID-19 on a ketogenic diet only
4:1 ketogenic diet formula
Dietary Supplement: Intubated patients with COVID-19 on a ketogenic diet only
4:1 ratio enteral ketogenic formula within 48 hours of intubation

Kelpoisuusehdot

Tutkimukseen soveltuvat iät 18 Years Vastaanottaja 18 Years
Sukupuolet, jotka ovat kelpoisia tutkimukseenAll
Hyväksyy terveelliset vapaaehtoisetJoo
Kriteeri

Inclusion Criteria:

- Patients age 18 and older.

- COVID-19 positive and respiratory failure requiring intubation

- Legally authorized representative

Exclusion Criteria:

- Unstable metabolic condition

- Liver failure

- Acute Pancreatitis

- Inability to tolerate enteral feeds, ileus, gastrointestinal bleeding

- Known Pregnancy

- Received propofol infusion within 24 hours

- Known fatty acid oxidation disorder or pyruvate carboxylase deficiency

Tulokset

Ensisijaiset tulosmittaukset

1. Change in the partial pressure of carbon dioxide (PaCO2) [Daily until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

PaCO2 is the partial pressure of carbon dioxide Units: millimeters of mercury

Toissijaiset tulosmittaukset

1. Change in minute ventilation [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Minute ventilation is the product of respiratory rate and tidal volume. Units: Liter per minute

2. Change in respiratory system compliance [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Respiratory system compliance measures the extent to which the lungs will expand. In a ventilated patient, compliance can be measured by dividing the delivered tidal volume by the [plateau pressure minus the total peep]. Units: liter/centimeter of water

3. Change in driving pressure [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Driving pressure is a measure of the strain applied to the respiratory system and the risk of ventilator-induced lung injuries Driving pressure = Plateau pressure - Total Positive end-expiratory pressure (PEEP) Units: centimeter of water

4. Change in ventilator synchrony [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Ventilator synchrony is the match between the patient's neural inspiratory time and the ventilator insufflation time

5. Change in mean arterial pressure [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Mean arterial pressure is the average pressure in a patient's arteries during one cardiac cycle. Mean arterial pressure = diastolic blood pressure +[1/3(systolic blood pressure - diastolic blood pressure)] Units: millimeter of mercury

6. Change in the fraction of inspired oxygen percentage of oxygen (FiO2) [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

FiO2: Fraction of Inspired Oxygen Percentage of oxygen in the air mixture that is delivered to the patient. Units: %

7. Change in the partial pressure of carbon dioxide (PaO2) to the fraction of inspired oxygen percentage of oxygen (FiO2) ratio [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen. Units: millimeter of mercury

8. Change in hydrogen ion activity (pH) [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

pH measures hydrogen ion activity. It is a conventional part of every arterial blood gas determination pH: no units.

9. Change in Bicarbonate (HCO3) [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Bicarbonate is a conventional part of every arterial blood gas determination Units: milliequivalents/Liter

10. Change in red blood cell count [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Red blood cell count measure anemia or hypoglycemia. Units: cells per liter

11. Change in white blood cell count [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

White blood cell count evaluates leukopenia or leukocytosis. Units: cells/liter

12. Change in white cell differential [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

White cell differential shows the amount of neutrophils, lymphocytes, basophils, eosinophils and may give some clue of the type of infection. Units: %

13. Change in hemoglobin levels [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Hemoglobin is an indirect way to measure red blood cells. Units: gram/deciliter

14. Change in hematocrit [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Hematocrit measures the volume percentage of red blood cells in blood. Units: %

15. Change in mean cell volume [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Mean cell volume is a measure of the average volume of a red blood corpuscle. Units: femtoliters

16. Change in mean cell hemoglobin [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Mean cell hemoglobin is the average mass of hemoglobin per red blood cell in a sample of blood. Units: picograms

17. Change in mean cell hemoglobin concentration [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Mean cell hemoglobin concentration is the average concentration of hemoglobin in a given volume of blood. Units: %

18. Change in platelet count [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Platelet count measures the number of platelets in the blood and determines thrombocytopenia or thrombocytosis. Units: platelets/liter

19. Change in red cell distribution width [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Red cell distribution width is a measure of the range of variation of red blood cell volume. Units: no units

20. Change in blood albumin level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Liver function test Units: gram/deciliter

21. Change in serum alkaline phosphatase level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Liver function test Units: international units/liter

22. Change in serum aspartate transaminase level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Liver function test Units: international units/liter

23. Change in serum alanine aminotransferase level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Liver function test Units: international units/liters

24. Change in blood urea nitrogen levels [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Kidney function test Units: milligram/deciliter

25. Change in serum calcium level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Kidney function test Units: milligram/deciliter

26. Change in serum chloride level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Kidney function test Units: millimole/liter

27. Change in serum potassium level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Kidney function test Units: millimole/liter

28. Change in serum creatinine level [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Kidney function test Units: gram/deciliter

29. Date patient is re-intubated or need mechanical ventilation for a second time [Up to 10 days]

If the patient needs mechanical ventilation for a second time, this information will be collected.

30. Length of intensive care unit stay [Up to 10 days]

Time from intensive care unit admission until death or transfer to hospital bed.

31. The total hospital stay [Up to 10 days]

Time from hospital admission to discharge from the hospital. This information will be collected.

32. Disposition at discharge [Up to 10 days]

Once the patient feels better and can leave the hospital, he/she will be discharged. The place of discharge (e.g. home, rehab facility, nursing home, etc), time and date will be collected.

33. Change in heart rate [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Heart rate: is the number of times a person's heart beats per minute

34. Change in the dosage of vasopressor medication [every 6 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: milligram

Muut lopputulokset

1. Change in total blood cholesterol level [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: milligram/deciliter

2. Change in blood low-density lipoprotein level [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: milligram/deciliter

3. Change in blood high-density lipoprotein level [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: milligram/deciliter

4. Change in blood triglycerides level [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: milligram/deciliter

5. Change in blood glucose level [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Glucose: sugar in blood. Units: millimole/liter

6. Change in blood glucagon level [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Glucagon: hormone release by pancreas that increase concentration of glucose in blood. Units: nanogram/liter

7. Change in blood free fatty acids level [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Free fatty acids are fatty acids that are produced from triglycerides and are measure in blood.

8. Change in blood insulin levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Hormone that regulates glucose. Units: insulin units/liter

9. Change in blood leptin levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Leptin helps regulate and alter long-term food intake and energy expenditure. Units: nanogram/deciliter

10. Change in blood insulin like growth factor 1 levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: nanomole/liter

11. Change in blood C‐reactive protein levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

C-reactive protein is a protein made by the liver that measures inflammation (e.g. pancreatitis). Units: microgram/milliliter

12. Change in blood interleukin-1β levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Cytokines are signaling molecules that measure inflammation.

13. Change in blood interleukin-6 levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Cytokines are signaling molecules that measure inflammation.

14. Change in blood interleukin-18 levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Cytokines are signaling molecules that measure inflammation.

15. Change in blood tumor necrosis factor alpha levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Cytokines are signaling molecules that measure inflammation.

16. Change in blood C-C motif chemokine ligand 2 (CCL2) levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Chemokine that mediates inflammation.

17. Change in blood C-C motif chemokine ligand 3 (CCL3) levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Chemokine that mediates inflammation.

18. Change in blood C-C motif chemokine ligand 4 (CCL4) levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Chemokine that mediates inflammation.

19. Change in blood B cell-attracting chemokine 1 (CXCL13) levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Chemokine that mediates inflammation.

20. Change in blood ferritin levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Ferritin stores iron inside of cells. Units: nanogram/milliliter

21. Change in blood betahydroxybutyrate levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: millimole/liter

22. Change in blood urine acetoacetate levels [At baseline and every 24 hours until the patient is wean off the ventilator or die, whichever came first, assessed up to 10 days]

Units: millimole/liter

Liity facebook-sivullemme

Täydellisin lääketieteellinen tietokanta tieteen tukemana

  • Toimii 55 kielellä
  • Yrttilääkkeet tieteen tukemana
  • Yrttien tunnistaminen kuvan perusteella
  • Interaktiivinen GPS-kartta - merkitse yrtit sijaintiin (tulossa pian)
  • Lue hakuusi liittyviä tieteellisiä julkaisuja
  • Hae lääkekasveja niiden vaikutusten perusteella
  • Järjestä kiinnostuksesi ja pysy ajan tasalla uutisista, kliinisistä tutkimuksista ja patenteista

Kirjoita oire tai sairaus ja lue yrtteistä, jotka saattavat auttaa, kirjoita yrtti ja näe taudit ja oireet, joita vastaan sitä käytetään.
* Kaikki tiedot perustuvat julkaistuun tieteelliseen tutkimukseen

Google Play badgeApp Store badge